statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, announced...

DiaMedica Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update May 9, 2024

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, today announced the...

DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke

Q4 2023 DiaMedica Therapeutics Inc Earnings Call Transcript

DiaMedica Therapeutics (NASDAQ:DMAC  Get Free Report) released its quarterly earnings data on Tuesday. The company reported ($0.14) earnings per share for the quarter, meeting analysts&#8217...

DiaMedica Therapeutics (NASDAQ:DMAC) Announces Quarterly  Earnings Results, Hits Estimates

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, today provided a...

DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results

This price move could indicate a change in the trend, and may be a buy signal for investors...

DiaMedica Therapeutics (DMAC, $3.02) price moved above its 50-day Moving Average on March 15, 2024

This price move could be a signal that DMAC may fall back below the higher band and head toward the middle band. Traders may consider selling the stock, shorting the stock, or exploring put options...

DiaMedica Therapeutics (DMAC, $3.23) price may drop as it broke higher Bollinger Band on Mar 04, 2024

This is a Bullish indicator signaling DMAC's price could rise from here. Traders may explore going long the stock or buying call options...

DiaMedica Therapeutics (DMAC, $3.07) Moving Average Convergence Divergence (MACD) Histogram turned positive on March 1, 2024

This indicator may be signaling DMAC's price has momentum to move higher, since its current price moved above its price 14 days ago. Traders may consider buying the stock or exploring call options...

DiaMedica Therapeutics (DMAC, $3.03) entered Uptrend as Momentum indicator ascends above 0 level on Feb 28, 2024

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke (AIS), today...

DiaMedica Therapeutics Announces Poster Presentation at International Stroke Conference

DiaMedica Therapeutics, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. It develops the DM199 product candidate, which focuses on acute ischemic stroke (AIS) and chronic kidney disease (CKD). The company was founded by Wayne Lautt on January 21, 2000 and is headquartered in Minneapolis, MN.

Watchers	1,408
52-Wk Low	$1.58
52-Wk High	$4.75

Volume	143,897.00
52-Wk High	$4.75
52-Wk Low	$1.58

Period	Estimated	Reported	Surprise	Result
Q1'24	-$0.16	--	--	N/A
Q4'23	-$0.14	-$0.12	14.29%	BEAT
Q3'23	-$0.13	-$0.12	5.26%	BEAT
Q2'23	-$0.18	-$0.16	9.43%	BEAT
Q1'23	-$0.16	-$0.20	-25.00%	MISSED

DMAC DiaMedica Therapeutics Inc

About

Feed

News

Earnings

Fundamentals